解码卵巢癌新兴亚型的基因组与功能图谱
该研究对243例患者的640个卵巢高级别浆液性癌(HGSC)肿瘤行全基因组测序,基于染色体不稳定性特征识别出五个HGSC亚型并在独立数据集中验证;两个HRD亚型治疗反应良好,三个HRP亚型具有独特结构改变和化疗反应差异,类器官实验显示亚型特异性CHK1抑制剂敏感性,提示prexasertib可能靶向治疗多数目前难治的HRP患者。
要点
- 基于染色体不稳定性特征将HGSC分为五个亚型,并在独立数据集中验证。
- 两个HRD亚型与BRCA1或BRCA2驱动改变相关,治疗反应良好。
- 三个HRP亚型结构改变、基因表达和化疗反应各异,类器官显示亚型特异性CHK1抑制剂敏感性。
核心结论
- HGSC肿瘤可分为功能与临床上不同的亚型,为开发针对目前缺乏有效方案的HRP肿瘤的定制治疗策略提供基础。
研究设计与样本
- 研究对243例患者的640个肿瘤行全基因组测序,基于染色体不稳定性特征分析结构变异图谱。
- 亚型在独立数据集中验证,并行类器官实验检测亚型特异性药物敏感性。
主要发现
- 基于染色体不稳定性特征分析识别出五个HGSC亚型,并在独立数据集中验证。
- 两个HRD亚型与BRCA1或BRCA2驱动改变相关,表现出良好的治疗反应。
- 三个HRP亚型具有独特结构改变、基因表达模式、肿瘤微环境相互作用及不同的化疗反应。
- 类器官实验显示亚型特异性CHK1抑制剂敏感性,提示prexasertib可能靶向治疗多数目前难治的HRP患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Ovarian high-grade serous carcinoma (HGSC) is characterized by pervasive genomic instability and high inter- and intra-tumor heterogeneity. Approximately half of HGSC tumors harbor homologous recombination deficiency (HRD), rendering them vulnerable to PARP inhibitors and platinum-based chemotherapy. In contrast, patients lacking HRD (HR-proficient, HRP) generally respond poorly to current therapies. To overcome heterogeneity and identify relevant HGSC subtypes, we characterized the genomic landscape of 640 tumors from 243 patients using whole-genome sequencing. Our chromosomal instability signature-based analysis characterized the structural variation landscape and revealed five HGSC subtypes, validated in an independent dataset. Two HRD subtypes, associated with BRCA1- or BRCA2-driven alterations, demonstrated favorable treatment responses. Strikingly, three HRP subtypes emerged, marked by unique structural alterations and gene expression patterns, tumor microenvironment interactions, and different chemotherapy responses. Notably, organoid experiments showed subtype-specific sensitivity to CHK1 inhibition, suggesting prexasertib as a potential targeted treatment for most currently untreatable HRP patients. SIGNIFICANCE: These findings demonstrate that HGSC tumors can be divided into functionally and clinically distinct subtypes, offering new insights into the underlying biology of HGSC and providing a foundation to develop tailored therapeutic strategies for HRP tumors, which currently lack effective options.
引用
- Micoli G, Lavikka K, Li Y, et al. Decoding the Genomic and Functional Landscape of Emerging Subtypes in Ovarian Cancer. Cancer Discov. 2025. PMID: 40736012. doi:10.1158/2159-8290.CD-25-0652
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。